The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio

01/19/22 • 22 min

Antibiotics act as a safety net for all of healthcare. They make medical procedures such as surgeries, childbirth and cancer treatments possible, but what happens when bacteria or other microorganisms become resistant to the drugs we use against them?

Back Bay Life Science Advisors’ Managing Director Peter Bak sits down with Marc Lemonnier, a molecular and cellular microbiologist and CEO of Antabio, a clinical stage company located in France developing novel antibiotic therapies, for a conversation on the current clinical landscape of novel agents to address antimicrobial resistance and the regional and global initiatives to tackle the issue.

Topics include:

The growing rates of antimicrobial resistance (AMR)
Which global organizations are at work on this issue and their list of priority pathogens a/k/a the world’s “most wanted deadly super bugs”?
How COVID 19 and the pandemic exacerbated the issue of AMR
Push and pull incentives and subscription models for innovative antimicrobials and how they work in various countries around the world
Why global access is a real issue and how to solve the problem

For more, read Back Bay Life Science Advisors' recent take on the role of investments in antimicrobials in STAT here.

Learn more about Antabio, a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO. www.antabio.com

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.

Topics include:

The growing rates of antimicrobial resistance (AMR)
Which global organizations are at work on this issue and their list of priority pathogens a/k/a the world’s “most wanted deadly super bugs”?
How COVID 19 and the pandemic exacerbated the issue of AMR
Push and pull incentives and subscription models for innovative antimicrobials and how they work in various countries around the world
Why global access is a real issue and how to solve the problem

For more, read Back Bay Life Science Advisors' recent take on the role of investments in antimicrobials in STAT here.

Learn more about Antabio, a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO. www.antabio.com

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.

Previous Episode

Best Practices for Successful Sell-Side Licensing, Partnering and M&A

Despite the heavy influx of capital over the past years, medtech or biopharma sell-side assignments can still be ripe with challenges. In this episode of Back Bay’s industry podcast, Back Bay Life Science Advisors’ investment banking team discuss best practices for successful sell-side licensing, partnering, and M&A, including:

Best practices for readying vital aspects of deal preparation
Identifying deal issues, red flags ahead of time
Articulation of the path forward, including indication and proof of concept and telling the story through to market
The importance of choosing the right partner and alignment for stakeholders, management, board, investors, internal champions and others
The most significant mistakes made in competitive intelligence, technology, position, IP regulatory strategies
Networking, contacts and how to know who’s going to be responsible for what and when

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn. Thank you for joining us.

Next Episode

The Commercial Potential of Optogenetic Therapies

Fifteen years ago, scientists discovered optogenetics, a technique of using light to stimulate light-sensitive receptors in order to turn brain cells “on” and “off" at the flip of a switch. Advances in optogenetics have allowed this technology to move from the laboratory to humans, and more recently biopharma companies have been quick to incorporate optogenetic therapies into their ophthalmology portfolios.

In this episode of Back Bay’s Life Science Report, Peter Bak is joined by Kevin Norman to discuss the promise and commercial considerations of optogenetics.

Topics include:

The basic principles of optogenetics and the diseases it may be a treatment for
How Big Pharma, biotech and VC view the promise of optogenetics for the future
Current issues, technical challenges and functional endpoints for active therapy trials like those with Nanoscope Therapeutics, GenSight Biologics, Allergan, etc.
The state of play for how optogenetics may be useful as a technology beyond the realm of ophthalmology, including cancer

Read Back Bay Life Science Advisors' latest industry article on optogenetics in Cell & Gene here.

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn and Twitter. Thank you for joining us.

If there's a question or subject you'd like us to cover, submit it here. It may be the topic of one of our upcoming podcasts.